pyrazines has been researched along with ps1145 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, J; Anderson, KC; Castro, A; Chauhan, D; Dang, L; Hayashi, T; Hideshima, T; Mitsiades, C; Mitsiades, N; Munshi, N; Palombella, V; Richardson, P | 1 |
| Anderson, KC | 1 |
| Drobyski, WR; Hari, P; Jacobs, P; Komorowski, R; Vodanovic-Jankovic, S | 1 |
| Abbruzzese, JL; Andtbacka, R; Arumugam, T; Khanbolooki, S; Kurzrock, R; Logsdon, CD; McConkey, DJ; Nawrocki, ST; Pino, MS | 1 |
| Fleissner, C; Hecht, M; Heider, U; Jakob, C; Kaiser, M; Kleeberg, L; Krebbel, H; Manz, RA; Mieth, M; Sezer, O; Sterz, J; von Metzler, I | 1 |
5 other study(ies) available for pyrazines and ps1145
| Article | Year |
|---|---|
NF-kappa B as a therapeutic target in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cell Division; Cell Line; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Heterocyclic Compounds, 3-Ring; Humans; I-kappa B Kinase; Immunoblotting; Intercellular Adhesion Molecule-1; Models, Chemical; Multiple Myeloma; NF-kappa B; Phosphorylation; Protease Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyridines; Time Factors; Tumor Cells, Cultured; Up-Regulation | 2002 |
Moving disease biology from the lab to the clinic.
Topics: Bone Marrow; Boronic Acids; Bortezomib; Cell Division; Drug Delivery Systems; Heterocyclic Compounds, 3-Ring; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Protease Inhibitors; Pyrazines; Pyridines; Thalidomide | 2003 |
NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145.
Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Colon; Cytokines; Graft Survival; Graft vs Host Disease; H-2 Antigens; Heterocyclic Compounds, 3-Ring; Leukocyte Common Antigens; Mice; Mice, Knockout; NF-kappa B; Pyrazines; Pyridines; Survival Rate | 2006 |
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; I-kappa B Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; NF-KappaB Inhibitor alpha; Pancreatic Neoplasms; Pyrazines; Pyridines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2006 |
Bortezomib inhibits human osteoclastogenesis.
Topics: Antineoplastic Agents; Apoptosis; Bone Resorption; Boronic Acids; Bortezomib; Cell Differentiation; Cell Lineage; Female; Heterocyclic Compounds, 3-Ring; Humans; In Vitro Techniques; Male; Multiple Myeloma; NF-kappa B; Osteoclasts; p38 Mitogen-Activated Protein Kinases; Pyrazines; Pyridines; RANK Ligand; Signal Transduction; Stem Cells; Transcription Factor AP-1; Vascular Endothelial Growth Factor A | 2007 |